BioTuesdays

Category - Markets

Gemphire Logo

HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as...

KalVista Pharmaceuticals Logo

BTIG starts KalVista at buy

BTIG launched coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $18 price target. The stock closed at $6.59 on August 30. KalVista is focused on developing a portfolio of oral plasma kallikrein...

Innate Pharma Logo

HCW starts Innate Pharma at buy

H.C. Wainwright initiated coverage of French-based Innate Pharma (PSE:IPH) with a “buy” rating and price target of €16.50. The stock closed at €10.70 on August 29. Analyst Swayampakula Ramakanth writes that Innate is...

Intra Cellular Therapies

Ladenburg ups Intra-Cellular to buy

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “buy” from “neutral” with a $36 price target, reflecting a positive update from the FDA about the company’s schizophrenia program. The stock closed...

Clementia

Leerink starts Clementia at OP

Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25. Clementia’s lead asset, palovarotene, is a small molecule...

Foamix Pharmaceuticals

HCW starts Foamix at buy

H.C. Wainwright initiated coverage of Foamix Pharmaceuticals (NASDAQ:FOMX) with a “buy” rating and $12 price target. The stock closed at $4.53 on Aug. 23. Analyst Raghuram Selvaraju writes that Foamix is a rapidly...

PTC Therapeutics

WB starts PTC Therapeutics at MP

William Blair initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “market perform” rating, citing a possibly tough road ahead for approval of the company’s ataluren in the U.S. The stock closed at $17.72 on Aug...

CymaBay

Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22. CymaBay is currently developing seladelpar for the lead...

Wave Life Sciences

Mizuho starts Wave Life Sciences at buy

Mizuho Securities initiated coverage of Wave Life Sciences (NASDAQ:WVE) with a “buy” rating and price target of $34. The stock closed at $17.50 on August 16. Analyst Salim Syed writes that Wave is an idea-rich, nucleic...